Buy Charles River Labs

By Linda McDonough • January 13, 2016

Charles River Labs (NYSE: CRL) is a contract research company that does drug discovery, safety and efficacy trials for drug companies and biotechs. While they have made many smaller acquisitions over the past few years, the Jan. 7 acquisition of WIL Research, for $585 million, will increase earnings dramatically

It gives the company a needed presence in Europe and exposure to smaller customers and new segments such as agriculture and industrial chemical testing (think bio-seeds and fertilizer safety).

We’ll have a full report in Tuesday’s issue of Profit Catalyst.

Buy CRL up to $80.

Stock Talk

Comments Oldest First

Comments Guidelines

Thomas De Uriarte

01/13/16 ‐ 3:03pm ET January 13, 2016 at 3:03pm ET

LINDA – I did not get the email for this alert! Can you check your system and see why I was left off the list? Thanks. Tom de

Linda McDonough

01/27/16 ‐ 4:42pm ET January 27, 2016 at 4:42pm ET

Absolutely Tom- I will look into it right now. I apologize for the technical glitch. We will make sure you receive these email alerts as they go out!
Linda

John Vandrasek

01/27/16 ‐ 4:17pm ET January 27, 2016 at 4:17pm ET

I also have not received any email alerts I have to go to this web site to review them when I think about it.

Jon D.

01/29/16 ‐ 2:05pm ET January 29, 2016 at 2:05pm ET

Hi Linda,
This is not a complaint I usually see alerts from one of several services I have through Investing daily.
But I don’t receive an email. I did look for where I could fill something in; but did not see it. I am online frequently so I usually can easily find when there is a new trade to put on. But if this is just something that is easily done at the office, then consider this as a request. Selling could be more time sensitive than buying so I may as well have another advantage.

Cheers,
Jon D.

Linda McDonough

01/31/16 ‐ 8:03pm ET January 31, 2016 at 8:03pm ET

Jon,

I will check in again with the IT department as I believe you should be receiving email alerts. I spoke with them last week and thought the issue had been righted. Sorry for the inconvenience and to all others that have been impacted.

I’ll get on with them first thing tomorrow and hopefully get this running smoothly!

Best,
Linda

Add New Comments

You must be logged in to post to Stock Talk

About The Author

Linda McDonough

Bio | Archive

Linda McDonough is a veteran hedge fund analyst who loves to break down company financial statements and identify market inefficiencies to uncover big opportunities. She believes in a boots-on-the-ground approach that includes surveying customers, interviewing company executives, or doing whatever it takes to see what others don't.

She's now brought her experience as a hedge fund analyst to subscribers of her Profit Catalyst Alert service. Her system identifies small- and mid-cap stocks that are about to move due to catalytic events that few others can identify...until it's too late. These events often times result in massive gains for her followers.